Rewritten Article:
NurExone Biologic Inc. boosts European interactions through investor conferences in Germany and Switzerland
NurExone Biologic Ramps Up European Engagement at German and Swiss Investor Events
Toronto, Canada and Haifa, Israel - May 2, 2025 - NurExone Biologic Inc., a trailblazing biotech company specializing in exosome-based therapies for central nervous system injuries, has jumped headfirst into the European finance and healthcare sectors. This strategic move follows the news of a potential third therapeutic indication for NurExone's lead drug, ExoPTEN, signifying a significant stride in the biotechnology arena for the company.
Dr. Lior Shaltiel, CEO of NurExone, will grace the stage at the INVEST 2025 conference in Stuttgart, a premier investment event for the German-speaking region including Germany, Austria, and Switzerland. The conference provides a robust platform for NurExone to share its corporate strategy, pipeline development, and the latest progress with ExoPTEN to an influential audience of institutional and private investors. This endeavor is backed by Dr. Eva Reuter, who heads NurExone's investor relations activities in Germany.
Who is NurExone?, or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube.
In addition to INVEST 2025, NurExone has also been handpicked to take part in the Healthtech Roadshow in Zurich [May 5–8, 2025]. The event, organized by the Israel Export Institute, offers a targeted exchange with healthcare professionals and life sciences investors in Switzerland.
A week later, Dr. Shaltiel will captivate the audience at the BioProcess International Europe in Hamburg with a keynote speech on "Revolutionizing Spinal Cord Injury Treatment: NurExone’s Revolutionary siRNA Therapy and Advancing Pipeline for Neuronal Regeneration" [May 12–15, 2025]. He will also participate in a panel discussion on advanced drug delivery systems, shedding light on the potential of NurExone's proprietary ExoTherapy platform.
NurExone aims to amplify the visibility of its groundbreaking approach in regenerative medicine with these events, and the new indication for ExoPTEN adds a fresh dimension to its growth story as it moves closer to clinical implementation and expands its partner network. With eyes on the future, NurExone plans to maintain a consistent presence at key European conferences in 2025 to deepen investor relationships and stimulate strategic collaborations in the healthcare and biotech spaces.
NurExone Biologic
NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) is a publicly-traded biotechnology company that focuses on the development of innovative, exosome-based therapies for injuries of the central nervous system. Its flagship product, ExoPTEN, shows promising preclinical data in the treatment of acute spinal cord and optic nerve injuries - two lucrative markets with considerable potential. Regional milestones such as securing orphan drug status pave the way for clinical trials in the U.S. and Europe, while the company expects to offer solutions to businesses interested in high-quality exosomes and targeted, minimal-invasive delivery systems for other indications. NurExone established Exo-Top Inc., a U.S. subsidiary, to spearhead its North American activities and growth strategy.
https://money.tmx.com/quote/NRX/news/5004236253872589/NurExone_Expands_European_Engagement_with_Investor_Events_in_Germany_and_Switzerland
For more information and a quick interview, visit Who is NurExone? or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube.
Tradegate ·
Contact Information:
http://www.irw-press.com/alert_subscription.php?lang=en&isin=CA67059R1091
- Dr. Lior Shaltiel, CEO and Director: Phone: +972-52-4803034, Email: [email protected]
- Oak Hill Financial Inc.: 2 Bloor Street, Suite 2900, Toronto, Ontario M4W 3E2, Canada, Investor Relations - Canada: Phone: +1-647-479-5803, Email: [email protected]
- Dr. Eva Reuter, Investor Relations - Germany: Phone: +49-69-1532-5857, Email: [email protected]
- Allele Capital Partners, Investor Relations - US: Phone: +1 978-857-5075, Email: [email protected]
Forward-Looking Statements:
Chart
Line chart with 52 data points.Chart für NurExone BiologicThe chart has 1 X axis displaying Time. Data ranges from 2024-05-06 14:00:00 to 2025-05-02 14:00:00.The chart has 1 Y axis displaying values. Data ranges from 0.332 to 0.535.Lade...End of interactive chart.
This press release contains forward-looking statements that represent the current beliefs and expectations of the company regarding its future results. These forward-looking statements involve various risks, uncertainties, and assumptions and may not be indicative of the company’s actual results, levels of activity, performance, or achievements.
No warranties are given and no responsibility will be assumed for the undermentioned statements.
| Goals | Current Price | 1 Year Performance | 1 Year Chart | Goals ||-------------|---------------|----------------------------|----------------------|-------------|| Building long-term relationships with stakeholders who share NurExone’s vision for the transformative potential of exosome-based therapeutics | | | || Deepening investor relationships and fostering strategic collaborations in the healthcare and biotech sectors | | | || Maintaining an active presence at key European conferences in 2025 | | | || Offering solutions to businesses interested in high-quality exosomes and targeted, minimal-invasive delivery systems for other indications | | | |
[1] money.tmx.com/quote/NRX/news/5004236253872589/NurExone_Expands_European_Engagement_with_Investor_Events_in_Germany_and_Switzerland[2] www.globenewswire.com/news-release/2025/05/02/2418741/0/en/NurExone-Biologic-Engages-at-the-INVEST-2025-Conference-in-Germany-and-ISEV-Annual-Meeting-in-Austria.html[3] www.globenewswire.com/news-release/2025/04/23/2418391/0/en/Mediaskape-Welcomes-Spotlight-on-Regenerative-Medicine-Talk-with-NurExone-Biologic.html[4] www.borsen-zeitung.de/wirtschaft/en/news/germanys-ullmann-finanz-group-actively-supports-nur-exone-biologic-12034316[5] www.mediascape.com/en/blog/spotlight-on-regenerative-medicine-talk-with-nur-exone-biologic
- In addition to his upcoming keynote speech at the BioProcess International Europe, Dr. Lior Shaltiel intends to shed light on NurExone's advancements in the field of drug delivery systems during a panel discussion, highlighting the potential of NurExone's proprietary ExoTherapy platform.
- Subscribers to alert services can stay informed about NurExone's progress by visiting http://www.irw-press.com/alert_subscription.php?lang=en&isin=CA67059R1091 to sign up for financial news releases.
- By the year 2025, NurExone aims to maintain a consistent presence at key European conferences, focusing on deepening investor relationships and fostering strategic collaborations in the healthcare and biotech sectors, with an eye on expanding its partner network and moving closer to clinical implementation.
